
Benzinga Pro data, Solid Biosciences (NASDAQ:SLDB) reported Q4 sales of $3.15 million. Earnings fell to a loss of $18.61 million, resulting in a 3.49% decrease from last quarter. Solid Biosciences collected $3.54 million in revenue during Q3, but reported earnings showed a $17.98 million loss.